Clinical Trial Update: Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study update describing Zanubrutinib in combination with Obinutuzumab for newly diagnosed follicular lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Follicular Lymphoma, Newly Diagnosed | Phase 2 | Status: RECRUITING